Description
Cisplatin is a platinum-based cross-linking agent that exhibits anticancer chemotherapeutic activity. Cisplatin induces crosslinks between guanine bases on DNA; it is clinically used to treat various forms of cancer. In lung cancer cells, cisplatin decreases phosphorylation of PI3K, Akt, and FOXO3a and induces apoptosis. Additionally, cisplatin modulates STAT signaling and immune responses in other models.
References
Hato SV, Khong A, de Vries IJ, et al. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014 Jun 1;20(11):2831-7. PMID: 24879823.
Liu H, Yin J, Wang C, et al. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells. Anticancer Drugs. 2014 Sep;25(8):898-907. PMID: 24814195.
Stordal B, Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life. 2007 Nov;59(11):696-9. PMID: 17885832.
Marcon L, Zhang X, Hales BF, et al. Effects of chemotherapeutic agents for testicular cancer on rat spermatogonial stem/progenitor cells. J Androl. 2011 Jul-Aug;32(4):432-443. PMID: 21088230.
ABOUT LKT LABS
LKT Laboratories is a biochemical supply company focused on the synthesis, purification, and isolation of small molecules for research applications. Its range of products exhibit known biological activities that have found uses in a wide array of research fields, especially cancer and neuroscience. These products include protein kinase inhibitors, ion channel modulators, and activators. LKT serves the global research community by supplying the highest purity products for use in cell culture models, animal studies, or as reference materials or analytical standards.